摘要
目的:探究赫赛汀与汉曲优在人表皮生长因子受体-2(Human epidermal growth factor receptor-2,HER2)阳性乳腺癌中应用效果。方法:选取2022年6月-2024年6月期间本院收治的58例HER2阳性乳腺癌患者作为研究对象。随机将患者分为汉曲优组(30例)和赫赛汀组(28例)。全部患者均接受新辅助化疗,在此基础上,两组采用不同的靶向治疗方法。汉曲优组使用汉曲优靶向治疗;赫赛汀组使用赫赛汀靶向治疗。分析比较两组的疗效、肝功能:丙氨酸氨基转移酶(Alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(Aspartate aminotransferase,AST)、碱性磷酸酶(Alkaline Phosphatase,ALP)以及不良事件发生情况。结果:两组的临床有效率无显著差异(P>0.05)。治疗前,两组的ALT、AST、ALP各项肝功能指标水平均无显著性差异(P>0.05)。治疗后,两组的各项肝功能指标水平均显著升高,但汉曲优组的ALT、AST、ALP水平均显著低于赫赛汀组(P<0.05)。汉曲优组的胃肠道反应、电解质紊乱的不良事件发生率相较于赫赛汀组显著降低(P<0.05)。结论:汉曲优与赫赛汀在HER2阳性乳腺癌患者中治疗效果相当,但汉曲优的使用对患者肝功能损伤小,不良事件发生率低,安全性更好。
Objective:To observe the safety and incidence of adverse events of hantreol and Herceptin in human epidermal growth factor receptor-2(HER2)positive breast cancer.Methods:The clinical data of 58 patients with HER2-positive breast cancer admitted to our hospital from June 2022 to June 2024 were retrospectively collected.All patients received neoadjuvant chemotherapy,on the basis of which,the two groups were treated with different targeted therapies.Hanquyou group was treated with Hanquyou targeted therapy.The herceptin group was treated with herceptin targeted therapy.The efficacy,liver function[alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP)]and adverse events of the two groups were collected and compared.Results:There was no significant difference in clinical effective rate between the two groups(P>0.05).Before treatment,there were no significant differences in the levels of ALT,AST and ALP liver function indexes between the two groups(P>0.05).After treatment,the levels of liver function indexes in both groups were significantly increased,but the levels of ALT,AST and ALP in Hanquyou group were significantly lower than those in Herceptin group(P<0.05).Compared with Herceptin group,the incidence of gastrointestinal reactions and adverse events of electrolyte disturbance in Hantreyou group was significantly decreased(P<0.05).Conclusion:Hantreu and Herceptin have the same therapeutic effect in patients with HER2-positive breast cancer,but the use of Hantreu has less damage to liver function,lower incidence of adverse events and better safety.
作者
李媛媛
Li Yuan-yuan(Department of General Surgery,Yuzhou People's Hospital,Yuzhou 461670,Henan,China)
关键词
乳腺癌
赫赛汀
汉曲优
安全性
不良事件
Breast cancer
Han Qu excellent
Herceptin
Security
Adverse event
作者简介
李媛媛,女,主治医师,主要从事乳腺外科临床工作,Email:yyyfly_yy69523@yeah.net。
